COMPLETED enrollment in our Phase 2 COVID-19 Clinical Trial

PARTNERING with BARDA in their DRIVe Solving Sepsis Initiative

Share on facebook
Share on twitter
Share on linkedin

March 2021: BioAegis CEO, Dr. Susan Levinson, appointed to BioNJ Board

We are excited to announce that BioAegis Chief Executive Officer, Dr. Susan Levinson, has been appointed to the BioNJ Board of Directors. 

BioNJ is the life sciences trade association for New Jersey with nearly 400 Member companies representing research-based life sciences organizations and stakeholders across the ecosystem from the largest biopharmaceutical companies to early stage start-ups. 

BioNJ is dedicated to ensuring a vibrant ecosystem where:

  • Science is Supported
  • Companies are Created
  • Drugs are Developed
  • Patients are Paramount

Because Patients Can’t Wait®, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources.

 

Susan L. Levinson, PhD

Susan brings to the Board her years as a researcher and entrepreneur, as well as her leadership roles in marketing, business development, R&D and business strategy.